Preimushchestva kombinirovannykh fiksirovannykh preparatov v dostizhenii kontrolya nad bronkhial'noy astmoy
- Authors: Knyazheskaya N.P1
-
Affiliations:
- Issue: No 15 (2013)
- Pages: 44-48
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/282370
- ID: 282370
Cite item
Open Access
Access granted
Abstract
Bronchial asthma (BA) is one of the most common diseases in modern society: in adult population it occurs in more than 5 % of cases, in children more frequently - up to 10 %. At present time, the combination of inhaled glucocorticosteroids (IGCS) with an inhaled long-acting P2-agonist forms the basis for the treatment of bronchial asthma in adults with moderate to severe disease and in children with severe disease. These classes of drugs (IGCS and long-acting β 2-agonists) should be considered as synergists due to their complementary effects on the molecular and receptor levels. Regular background therapy, including the use of combined drugs, should provide adequate asthma control in many patients. Currently, new combination of fluticasone propionate and salmeterol with the trade name Tevacomb was developed; the dosage of this drug corresponds to the original drug in metered dose inhaler.
Keywords
Full Text
References
- Global Initiative for Asthma. Workshop Report, 2006. http://www.ginasthma.com/download. asp?intId=217
- http://www.ginasthma.org (last accessed 21 November 2012).
- Barnes PJ. Clinical outcome of adding long-acting в-agonists to inhaled corticosteroids. Respir Med 2001;95(Suppl B):12-16.
- Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting e2-agonists and corticosteroids. Eur Respir J 2002;19:182-91.
- Bateman ED, Boushey HA, Bousquet J, et al. Pedersen SE for the GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am J Respir Crit Care Med 2004;170:836-44.
- Condemi JJ, Goldstein S, Kalberg C, et al. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group. Ann Allergy Asthma Immunol 1999;82:383-89.
- Stoloff S, Poinsett-Holmes K, Dorinsky PM. Combination therapy with inhaled long-acting beta2-agonists and inhaled corticosteroids: a paradigm shift in asthma management. Pharmacotherapy 2002;22:212-26.
- Roth M, Johnson PR, Rudiger JJ, et al. Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002;360:1293-99.
- Lim KG. Management of persistent symptoms in patients with asthma. Mayo Clin Proc 2002;77:1333-38.
- http://www.fda.gov/
- Barnes NC, Jacques L, Goldfrad C, Bateman ED. Initiation of maintenance treatment with salmeterol/fluticasone propionate 50/100 μg bd versus fluticasone propionate 100 yg bd alone in patients with persistent asthma: Integrated analysis of four randomised trials. Respiratory Medicine 2007;101:2358-65.
- Bousquet J, Bateman E, Boushey H, Busse W, et al. The effect of oral corticosteroids and high-dose combination therapy on achieving control of refractory asthma. J of Allergy Clin Immunol 113;2:113.
- Dowling RB, Rayner CFJ, Rutman A, et al. Effect of salmeterol on Pseudomonas aeruginosa infection of respiratory mucosa. Am J Respir Crit Care Med 1997;155;327-36.
- Dowling RB, Jonson M, Cole PJ, Wilson R. Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro. Eur Respir J1998;11:86-90.
- Proud D, Reynolds CJ, Lichtenstein LM, et al. Intranasal salmeterol inhibits allergen-induced vascular permeability but not mast cell activation or cellular infiltration. Clin Exp Allergy 1998;28:868-75.
- Li X, Ward C, Thien F, et al. An antiinflammatory effect of salmeterol, a long-acting beta2-Agonist, assessed in airway biopsies and bronchoalveolar lavage in Asthma. Am J Respir Crit Care Med 1999;160:1493-98.
- Mak JCW, Nishikawa M, Shirasaki H, et al. Protective effects of a glucocorticoid on down-regulation of pulmonary e2-adrenergic receptors in vivo. J Clin Invest 1995;96:99-106.
- Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respit Care Med 1996; 153:1481-88.
- Kirby S, Falcoz C, Daniel MJ, et al. Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. Eur J Clin Pharmacol 2001;56:781-91.
- Bateman ED, Boushey HA, Bousquet J, et al.; GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.Am J Respir Crit Care Med. 2004;170(8):836-44.
- Lundback B, Ronmark E, Lindberg A, et al. Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate. Respir Med 2006; 100(1):2-10.
- Панина Н.Т. Применение препарата Тевакомб в лечении больных бронхиальной астмой // Атмосфера. Пульмонология и аллергология 2011. № 4. С. 28-30.
- Зайцева О.В., Ильина Н.И. и др. Заключение Совета экспертов // Атмосфера. Пульмонология и аллергология 2013. № 13. С. 20-1.
- Федосеенко С.Е., Шмелев Е.И. Эффективность и безопасность препарата Тевакомб в лечении больных бронхиальной астмой с позиции доказательной медицины // Атмосфера. Пульмонология и аллергология 2012. № 2(45). С. 1-4.
Supplementary files
